FDA reviewers: J&J's canagliflozin effective but safety concerns

FDA reviewers generally supported the efficacy of diabetes drug Invokana canagliflozin from Johnson & Johnson (NYSE:JNJ), but raised a number of safety concerns with the sodium-glucose cotransporter 2 (SGLT2) inhibitor. In SGLT2 inhibitor Forxiga dapagliflozin at a 2011 EMDAC meeting. The panel voted against approval of the diabetes product from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Bristol-Myers Squibb Co. (NYSE:BMY), and FDA subsequently issued a complete response letter (see BioCentury, July 25, 2011). ...